New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
09:03 EDTMEIPMEI Pharma announces first patient has been doses in trial of Pracinostat
MEI Pharma announced that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase, or HDAC, inhibitor, in patients with myelodysplastic syndrome, or MDS, who either failed to respond or maintain a response to a hypomethylating agent alone.
News For MEIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
08:35 EDTMEIPMEI Pharma reports FY15 EPS ($1.16), consensus ($1.21)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use